PROTEUS May Mean New SOC for Some Prostate Cancers

For people with localized, high-risk prostate cancer, treatment with 6 months of apalutamide and androgen deprivation therapy (ADT) both before and after surgery reduces the risk of metastases and death compared with perioperative ADT alone, according to results of the phase III PROTEUS trial. At 5 years, 78.2% of patients who received apalutamide plus ADT were alive and free from metastasis, compared with 73.5% in the ADT only group.